FORM 10-QSB

(Mark One)

- [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 1997; or
- [-] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to

Commission File Number:

FORENSIC TECHNOLOGIES INTERNATIONAL CORPORATION (Exact Name of Registrant as Specified in its Charter)

MARYLAND

52-1261113 ____ (I.R.S. Employer

Identification No.)

_____ _ _____ (State or other Jurisdiction of Incorporation or Organization)

> 2021 Research Drive, Annapolis, Maryland 21401 _____ -----

> > (Address of Principal Executive Offices) (Zip Code)

> > > (410) 224-8770 · · · · ·

(Registrant's Telephone Number, Including Area Code)

(Former name, former address and former fiscal year, . if changed since last report) ------

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

[X] Yes [] No

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.

Class	Outstanding at August 14, 1997
Common Stock, par value	4,526,912 shares

\$.01 per share

FORENSIC TECHNOLOGIES INTERNATIONAL CORPORATION TNDEX

PART I	FINANCIAL INFORMATION	Page
Item 1.	Financial Statements	3 to 9
Item 2.	Management's Discussion and Analysis of Results of Operations and Financial Condition	10
PART II	OTHER INFORMATION	
Item 4.	Submission of Matters to a Vote of Security Holders	11
Item 6.	Exhibits and Reports on Form 8-K	
	Financial Data Schedule	12

Forensic Technologies International Corporation and Subsidiary

Consolidated Balance Sheets (Unaudited)

	DECEMBER 31, 1996	JUNE 30, 1997
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 5,893,897 \$	5,324,053
Accounts receivable, less allowance of \$250,877 in 1996 and		
\$262,998 in 1997 Unbilled receivables, less allowance of \$125,439 in 1996 and	6,296,599	6,724,594
\$149,441 in 1997	3 006 953	3,821,051
Inventory	332,828	332,828
Income taxes receivable	111,471	-
Deferred income taxes	185,926	185,926
Prepaid expenses		673,068
Total current assets		17,061,520
Property and equipment:		
Buildings	411,241	411,241
Furniture and equipment		9,481,890
Leasehold improvements	863,821	1,248,989
	9,730,435	11,142,120
Accumulated depreciation and amortization	(5,624,060)	(6,307,404)
	4,106,375	4,834,716
Other assets	515,722	581,263
Total assets	\$ 20,868,425	

	DECEMBER 31, 1996	
LIABILITIES AND STOCKHOLDERS' EOUITY		
Current liabilities:		
Accounts payable	\$ 1,502,076	\$ 1,318,629
Accrued compensation expense	783,108	776.015
Income taxes payable	_	368.922
Current portion of capital lease obligations	52,804	130,642
Advances from clients	585,562	
Other current liabilities	11,063	-
Total current liabilities		3,120,598
Long-term debt and capital lease obligations, less current portion		
	,	250,964
Deferred income taxes	103,938	103,938
Commitments and contingent liabilities	-	-
Stockholders' equity:		
Preferred stock, \$.01 par value; 4,000,000 shares authorized, none outstanding		
Common stock, \$.01 par value:		
Authorized shares - 16,000,000		
Shares issued and outstanding and not subject to repurchase -		
4,516,912 in 1996, 4,526,912 in 1997	- /	45,269
Additional paid-in capital		14,453,402
Retained earnings		4,503,328
Total stockholders' equity		19,001,999
Total liabilities and stockholders' equity	\$ 20,868,425	\$ 22,477,499

Consolidated Statements of Operations (Unaudited)

	THREE MONTHS ENDED 1996	
Revenues	(Restated - Note 1) \$ 8,008,204 \$	9,471,409
Direct cost of revenues Selling, general and administrative expenses	4,414,802 2,467,289	3,110,629
Total costs and expenses	6,882,091	
	1,126,113	1,128,994
Other income (expenses): Interest and other income Interest expense	50,546 (60,953)	
	(10,407)	74,459
Income before income taxes	1,115,706	1,203,453
Income taxes	464,709	493,416
Net income	\$ 650,997 \$	710,037
Earnings Per Share Data: Per common and common equivalent share:	\$0.19	
Per common share, assuming full dilution:	\$0.17	\$0.15

Forensic Technologies International Corporation and Subsidiary

Consolidated Statements of Operations (Unaudited)

	SIX MONTHS ENDED JUNE 30 1996 1997		
	(Res	tated - Note 1)	
Revenues	Ş	14,973,858	\$ 19,010,958
Direct cost of revenues Selling, general and administrative expenses		8,165,772 5,094,192	10,393,458 6,460,173
Total costs and expenses		13,259,964	16,853,631
		1,713,894	2,157,327
Other income (expenses): Interest and other income Interest expense		82,836 (141,386)	172,263 (42,095)
		(58,550)	130,168
Income before income taxes			2,287,495
Income taxes		700,011	937,873
Net income		955,333	\$ 1,349,622
Earnings Per Share Data: Per common and common equivalent share:		\$0.33	\$0.29
Per common share, assuming full dilution:		\$0.27	\$0.29

		SIX MONTHS ENDED JUNE 30 1996 1997				
OPERATING ACTIVITIES						
Net income	\$	955,333	\$	1,349,622		
Adjustment to reconcile net income to net cash		,		, , -		
provided by (used in) operating activities:						
Depreciation		333,398		616,712		
Amortization		55,428		77,023		
Non-cash compensation		21,682		-		
Provision for doubtful accounts		45,489		36,123		
Deferred income taxes		17,189		-		
Loss on disposal of assets		2,056		3,234		
Accrued loss on disposal of discontinued division		(478,828)		5,254		
Changes in operating assets and liabilities:				_		
Accounts receivable		(407,124)		(439,069)		
Unbilled receivables		(1,032,611)		(839,147)		
Prepaid expenses		(101,736)		(254,414)		
Accounts payable		272,412		(183,447)		
Accrued compensation expense		(203 , 989)		(7,093)		
Income taxes payable		140,146		480,393		
Deferred revenue		(138,889)		-		
Advances from client		133,196		(59 , 172)		
Other current liabilities		79,664		(11,063)		
Accounting adjustment due to pooling		71,913		-		
Net cash provided by (used in) operating activities		(235,271)		769,702		
INVESTING ACTIVITIES						
Purchase of property and equipment		(787,118)		(1,202,225)		
Proceeds from sale of property and equipment		3,000		-		
Change in other assets		3,753		(68,049)		
Net cash used in investing activities		(780 , 365)		(1,270,274)		
FINANCING ACTIVITIES						
Issuance of Class A Common Stock		11,230,863		-		
Repurchase of Class A Common Stock		(130,260)		-		
Repurchase of Class A Common Stock subject to repurchase		(310,930)		-		
Repurchase of Class B Common Stock		(300)		_		
Exercise of stock options		(300)		23,799		
Net borrowings (repayments) under line of credit		(1,493,808)		2J, 199		
Payments of capital lease obligations		(1,493,808) (40,013)		(93,071)		
Dividends paid		(62,396)		(93,071)		
Dividends para						
Net cash provided by (used in) financing activities		9,193,156		(69,272)		
		0 177 500				
Net increase in cash and cash equivalents		8,177,520		(569,844)		
Cash and cash equivalents at beginning of period		244,925		5,893,897		
Cash and cash equivalents at end of period	\$	8,422,445				
	=====					

FORENSIC TECHNOLOGIES INTERNATIONAL CORPORATION AND SUBSIDIARY NOTES TO FINANCIAL STATEMENTS (UNAUDITED) JUNE 30, 1997

1. BASIS OF PRESENTATION

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and Item 310(b) of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto included in the Company's annual report on Form 10-KSB for the year ended December 31, 1996.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six month period ended June 30, 1997 are not necessarily indicative of the results that may be expected for the year ended December 31, 1997.

On September 30, 1996 the Company acquired all of the outstanding common stock of Teklicon, Inc. ("Teklicon") in exchange for 415,000 shares of common stock. The acquisition was accounted for as a pooling of interests and, accordingly, the Company's financial statements have been restated for all periods prior to the merger to include the financial position, results of operations, and cash flows of Teklicon. The accompanying consolidated statements of operations, and cash flows for the three and six month periods ending June 30, 1996 have been restated to reflect the acquisition of Teklicon.

2. OPTION GRANTS

On March 25, 1997, the Board of Directors approved the issuance of options to purchase 300,000 shares of Class A Common Stock to key employees. The exercise prices of the shares granted range from \$6.00 to \$9.50 per share, at or above the estimated fair market value of a share of Class A Common Stock at the date of grant, and the options vest ratably over a three year period.

In addition, options to purchase 4,200 shares of Class A Common Stock were issued on May 21, 1997 to each of the non employee directors of the Company under the Formula Option of the 1997 Stock Option Plan. An aggregate of 16,800 options were granted at an exercise price of \$7.63 per share.

FORENSIC TECHNOLOGIES INTERNATIONAL CORPORATION AND SUBSIDIARY NOTES TO FINANCIAL STATEMENTS (UNAUDITED) JUNE 30, 1997

3. EARNINGS PER SHARE

The following table summarizes the computations of earnings per share for the three month and six month periods ended June 30, 1996 and 1997. This table should be read in conjunction with Note 2 to the 1996 audited financial statements.

	THREE MONTHS ENDED JUNE 30			SIX MONTHS ENDED JUNE 30				
				1997				1997
	(UNAUDITED))	(UNAUDITED)			
Primary: Weighted average number of shares of common stock outstanding during the period Dilutive effect of other options and warrants - based on treasury stock method using average				4,526,912				
market price		223,950		168,325		216,346		160,653
Total common and common equivalent shares of stock considered outstanding during the year				4,695,237				4,683,863
Net income	\$	650 , 997	\$	710,037	\$	955 , 333	\$	1,349,622
Per share amount	\$	0.19	\$	0.15	\$	0.33	\$	
<pre>Fully diluted: Weighted average number of shares of common stock outstanding during the period Dilutive effect of other options and warrants - based on treasury stock method using market price at the end of the period Assumed conversion of Series A Redeemable Convertible Preferred Stock</pre>				4,526,912 191,350 -				4,523,210 191,350 -
Assumed conversion of 8% Convertible Subordinated Debentures		178,615		-		278,308		-
Total fully diluted securities considered outstanding during the year				4,718,262				4,714,560
Net income				710,037				
Add 8% Convertible Subordinated Debenture interest, net of income taxes		10,077		-		31,402		-
	\$	661,074	\$	710,037	\$,		1,349,622
Per share amount	Ş	0.17	\$	0.15	\$	0.27	\$	

In February 1997, the Financial Accounting Standards Board issued Statement No. 128, "Earnings Per Share", which is required to be adopted on December 31, 1997. At that time, the Company will be required to change the method currently used to compute earnings per share and to restate all prior periods. The impact of Statement 128 on the calculation of earnings per share is not expected to be material.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

Revenues for the second quarter and six months ended June 30, 1997, increased 18.3%, to \$9.5 million and 27.0% to \$19.0 million over the same periods in 1996, respectively. These increases are primarily the result of revenues from visual communication services growing 36.4% to \$4.6 million and 61.0% to \$9.3 million during the quarter and six months, respectively, attributable to higher levels of active trials during the periods and the success of an integrated approach to the marketing of the Company's services. Trial consulting decreased 15.2% during the quarter and 4.9% during the periods. Engineering revenues grew 17.5% and 11.6% during the quarter and six months, respectively, attributable to increased sales by last year's acquisitions of Teklicon and Anamet Laboratories.

Direct costs, as a percentage of revenue, were approximately the same during the second quarter and six months of 1997 and 1996, as a result of managing the mix of internal and external resources to meet the demands for the Company's services. Selling, general and administrative expenses increased as a percent of revenue during the quarter as the growth in fixed and semi-variable costs exceeded the increase in revenues. Interest expense decreased in the quarter and six months due to no usage on the line of credit during 1997; borrowings under the line of credit during 1996 were repaid from funds received from the sale of Common Stock in May, 1996. Unused funds from such sale have been invested to increase interest income subsequent to May, 1996.

Cash flow provided by operations during the six months, were offset by additional investments in office facilities and computer equipment. These investments assist the Company in providing enhanced services to its clients. The net decrease in cash was funded by the remaining balance of the net proceeds from the sale of the Company's stock in May, 1996. Such balance, approximately \$5.3 million, will be used for working capital and other general corporate purposes, including possible acquisitions.

Item 4. Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders was held on May 21, 1997. The following matters, solicited pursuant to Regulation 14A under the Exchange Act, were considered and voted upon at the Annual Meeting:

- (i) The election of two Class I Directors, each for a three-year term;
- Adoption of the Employee Stock Purchase Plan of the Company by a vote of 2,718,798 For, 278,840 Against and 9,090 Abstaining;
- (iii) Adoption of the 1997 Stock Option Plan of the Company by a vote of 2,415,259 For, 550,140 Against and 15,640 Abstaining;
- (iv) Ratification of Ernst & Young LLP as the Company's independent auditors for the fiscal year ending 1997 by a vote of 3,899,429 For, 3,500 Against and 1,268 Abstaining.

```
5
                                       1
                              US DOLLAR
        6-MOS
          DEC-31-1997
            JAN-01-1997
                JUN-30-1997
                  1 5,324,053
                                 0
                  10,958,084
412,439
332,828
          332,828

17,061,520

11,142,120

6,307,404

22,477,499

3,120,598

0

0

0

45,269

18,956,730

499
22,477,499
                    19,010,958
                19,010,958
10,393,458
                    16,853,631
                        0
                           0
                  42,095
             42,095
2,287,495
937,873
1,349,622
0
0
1,349,622
0 29
                          0.29
                            0.29
```